Approaches for management of Clostridium difficile infection continually evolve as research reveals shifts in epidemiology, microbial pathogenesis, disease severity states, and response to therapy. These new discoveries significantly impact diagnostic and therapeutic strategies, given the high morbidity associated with this common nosocomial infectious diarrhea. Critically ill patients are at an increased risk of developing diarrheal illness like C.difficile and succumbing to potentially fatal complications of this infection. Early diagnosis of severe disease state may improve patient outcomes. In this article, we review treatment strategies and new approaches for the management of C. difficile in critically ill patients.
McDonaldLCOwingsMJerniganDB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis. 2006;12(3):409–415.
6.
KellyCPLaMontJT. Clostridium difficile--more difficult than ever. N Engl J Med. 2008;359(18):1932–1940.
7.
LooVGPoirierLMillerMA. A predominantly clonal multi-institutional outbreak of clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353(23):2442–2449.
8.
SunenshineRHMcDonaldLC. Clostridium difficile-associated disease: new challenges from an established pathogen. Cleve Clin J Med. 2006;73(2):187–197.
9.
BartlettJG. Clostridium difficile: progress and challenges. Ann N Y Acad Sci. 2010;1213:62–69.
10.
McDonaldLCKillgoreGEThompsonA. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353(23):2433–2441.
11.
VerdoornBPOrensteinRRosenblattJE. High prevalence of tcdC deletion-carrying Clostridium difficile and lack of association with disease severity. Diagn Microbiol Infect Dis. 2010;66(1):24–28.
12.
CloudJNoddinLPressmanAHuMKellyC.Clostridium difficile strain NAP-1 is not associated with severe disease in a nonepidemic setting. Clin Gastroenterol Hepatol. 2009;7(8):868–873, e862.
13.
KellyCPLaMontJT. Antibiotic-associated diarrhea, Pseudomembranous Enterocolitis, and Clostridium difficile-associated diarrhea and colitis. Sleisenger and Fordtran's Gastrointestinal and Liver Disease - 2 Volume Set: Pathophysiology, Diagnosis, Management. Vol 2. 9th ed. Saunders (Philadelphia; PA); 2010:1889–1903.
14.
BouzaEBurrilloAMunozP. Antimicrobial therapy of Clostridium difficile-associated diarrhea. Med Clin N Am. 2006;90:1143.
15.
HicksonM. Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection. Therap Adv Gastroenterol. 2011;4(3):185–197.
16.
BoboLDDubberkeERKollefM. Clostridium difficile in the ICU: the struggle continues. Chest. 2011;140(6):1643–1653.
17.
UngerJAWhimbeyEGravettMGEschenbachDA.The emergence of Clostridium difficile infection among peripartum women: a case-control study of a C. difficile outbreak on an obstetrical service. Infect Dis Obstet Gynecol. 2011:267249. doi:10.1155/2011/267249
18.
GerdingDNMutoCAOwensRCJr. Measures to control and prevent Clostridium difficile infection. Clin Infect dis. 2008;46(suppl 1):S43–S49.
19.
BlissDZJohnsonSSavikKClabotsCRWillardKGerdingDN. Acquisition of clostridium difficile and clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann intern Med. 1998;129(12):1012–1019.
20.
IizukaMItouHKonnoS. Elemental diet modulates the growth of clostridium difficile in the gut flora. Aliment Pharmacol Ther. 2004;20(suppl 1):151–157.
21.
O'KeefeSJ. Tube feeding, the microbiota, and clostridium difficile infection. World J Gastroenterol. 2010;16(2):139–142.
22.
O'KeefeSJLeeRBAndersonFP. Physiological effects of enteral and parenteral feeding on pancreaticobiliary secretion in humans. Am J Physiol Gastrointest Liver Physiol. 2003;284(1):G27–G36.
23.
KellyCP. A 76-year-old man with recurrent clostridium difficile-associated diarrhea: review of C. difficile infection. JAMA. 2009;301(9):954–962.
24.
KellyCPPothoulakisCLamontJTClostridium difficile colitis. N Engl J Med. 1994;330(4):259–260.
25.
KirkpatrickIDGreenbergHM. Evaluating the CT diagnosis of clostridium difficile colitis: should CT guide therapy?AJR Am J Roentgenol. 2001;176(3):635–639.
26.
BoboLDDubberkeER. Recognition and prevention of hospital-associated enteric infections in the intensive care unit. Crit Care Med. 2010;38(suppl 8):S324–S334.
27.
CohenSHGerdingDNJohnsonS. Clinical practice guidelines for clostridium difficile infection in adults: 2010 update by the Society For Healthcare Epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–455.
28.
ChapinKCDickensonRAWuFAndreaSB. Comparison of five assays for detection of clostridium difficile toxin. J Mol Diagn. 2011;13(4):395–400.
29.
DeshpandeAPasupuletiVRolstonDD. Diagnostic accuracy of real-time polymerase chain reaction in detection of clostridium difficile in the stool samples of patients with suspected clostridium difficile infection: a meta-analysis. Clin Infect Dis. 2011;53(7):e81–e90.
30.
ShethSGLaMontJT. Gastrointestinal problems in the chronically critically ill patient. Clin Chest Med. 2001;22(1):135–147.
ZarFABakkanagariSRMoorthiKMDavisMB. A comparison of vancomycin and metronidazole for the treatment of clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45(3):302–307.
33.
ZilberbergMDShorrAFMicekSTDohertyJAKollefMH. Clostridium difficile-associated disease and mortality among the elderly critically ill. Crit Care Med. 2009;37(9):2583–2589.
34.
WilcoxMHHoweR. Diarrhoea caused by clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother. 1995;36(4):673–679.
35.
DubberkeERGerdingDNClassenD. Strategies to prevent clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol. 2008;29(suppl 1):S81–S92.
36.
TeasleyDGGerdingDNOlsonMM. Prospective randomised trial of metronidazole versus vancomycin for clostridium-difficile-associated diarrhoea and colitis. Lancet. 1983;2(8358):1043–1046.
37.
AslamSMusherDM. An update on diagnosis, treatment, and prevention of clostridium difficile-associated disease. Gastroenterol Clin North Am. 2006;35(2):315–335.
38.
WenischCParschalkBHasenhundlMHirschlAMGraningerW. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of clostridium difficile-associated diarrhea. Clin Infect Dis. 1996;22(5):813–818.
39.
Al-NassirWNSethiAKNerandzicMMBobulskyGSJumpRLDonskeyCJ. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis. 2008;47(1):56–62.
40.
BartlettJG. New antimicrobial agents for patients with clostridium difficile infections. Curr Infect Dis Rep. 2009;11(1):21–28.
41.
ShenEPSurawiczCM. Current treatment options for severe clostridium difficile-associated disease. Gastroenterol Hepatol. 2008;4(2):134–139.
42.
LamontagneFLabbeACHaeckO. Impact of emergency colectomy on survival of patients with fulminant clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg. 2007;245(2):267–272.
43.
GashKBrownEPullyblankA. Emergency subtotal colectomy for fulminant clostridium difficile colitis--is a surgical solution considered for all patients?Ann R Coll Surg Engl. 2010;92(1):56–60.
44.
MullaneKMMillerMAWeissK. Efficacy of fidaxomicin versus vancomycin as therapy for clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis. 2011;53(5):440–447.
45.
KyneLWarnyMQamarAKellyCP. Association between antibody response to toxin A and protection against recurrent clostridium difficile diarrhoea. Lancet. 2001;357(9251):189–193.
46.
NealMDAlverdyJCHallDESimmonsRLZuckerbraunBS.Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated clostridium difficile associated disease. Ann Surg. 2011;254(3):423–427; discussion 427-429.
47.
McFarlandLVElmerGWSurawiczCM. Breaking the cycle: treatment strategies for 163 cases of recurrent clostridium difficile disease. Am J Gastroenterol. 2002;97(7):1769–1775.
KellyCPKyneL. The host immune response to clostridium difficile. J Med Microbiol. 2011;60(Pt 8):1070–1079.
50.
LouieTJMillerMAMullaneKM. Fidaxomicin versus vancomycin for clostridium difficile infection. N Engl J Med. 2011;364(5):422–431.
51.
GareyKWGhantojiSSShahDN. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with clostridium difficile infection. J Antimicrob Chemother. 2011;66(12):2850–2855.
52.
DubberkeERReskeKAOlsenMAMcDonaldLCFraserVJ. Short- and long-term attributable costs of clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis. 2008;46(4):497–504.
53.
GordinFMSchultzMEHuberRAGillJA. Reduction in nosocomial transmission of drug-resistant bacteria after introduction of an alcohol-based handrub. Infect Control Hosp Epidemiol. 2005;26(7):650–653.
54.
AbbettSKYokoeDSLipsitzSR. Proposed checklist of hospital interventions to decrease the incidence of healthcare-associated clostridium difficile infection. Infect Control Hosp Epidemiol. 2009;30(11):1062–1069.
TannockGWMunroKTaylorC. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of clostridium difficile-infected patients than does vancomycin. Microbiology. 2010;156(Pt 11):3354–3359.
57.
JohnsonSSchrieverCGalangMKellyCPGerdingDN. Interruption of recurrent clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007;44(6):846–848.
58.
MusherDMLoganNBresslerAMJohnsonDPRossignolJF. Nitazoxanide versus vancomycin in clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis. 2009;48(4):e41–e46.
59.
GerdingDNJohnsonS. Management of clostridium difficile infection: thinking inside and outside the box. Clin Infect Dis. 2010;51(11):1306–1313.
60.
HerpersBLVlaminckxBBurkhardtO. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory clostridium difficile infection. Clin Infect Dis. 2009;48(12):1732–1735.
61.
KyneLWarnyMQamarAKellyCP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000;342(6):390–397.
62.
LeeBYPopovichMJTianY. The potential value of clostridium difficile vaccine: an economic computer simulation model. Vaccine. 2010;28(32):5245–5253.
63.
AbougergiMSKwonJH. Intravenous immunoglobulin for the treatment of clostridium difficile infection: a review. Dig Dis Sci. 2011;56(1):19–26.
64.
LowyIMolrineDCLeavBA. Treatment with monoclonal antibodies against clostridium difficile toxins. N Engl J Med. 2010;362(3):197–205.
65.
AboudolaSKotloffKLKyneL. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun. 2003;71(3):1608–1610.
66.
NaXKellyC.Probiotics in clostridium difficile infection. J Clin Gastroenterol. 2011;45(suppl):S154–S158.
67.
PillaiANelsonR.Probiotics for treatment of clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev. 2008;(1):CD004611.
68.
YoonSSBrandtLJ. Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. J Clin Gastroenterol. 2010;44(8):562–566.
69.
KhorutsADicksvedJJanssonJKSadowskyMJ. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent clostridium difficile-associated diarrhea. J Clin Gastroenterol. 2010;44(5):354–360.
